Foresight Biosciences aims to produce innovation for the advancement of glycobiology research and therapeutics.  According to Ronny, Hughes Ph.D., president and chief scientist at Foresight Biosciences, “The number of glycosylated eukaryotic therapeutic proteins is increasing each year and is driving a growing market for products to assist this research. We have produced a library of enzymes to enable the attachment of carbohydrates and ligands to glycopeptides.”  Hughes also noted the company is currently using this technology to develop a new kind of therapeutic platform for the treatment of influenza.